214 related articles for article (PubMed ID: 11240614)
1. Current therapy for rare factor deficiencies.
Di Paola J; Nugent D; Young G
Haemophilia; 2001 Jan; 7 Suppl 1():16-22. PubMed ID: 11240614
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive care for hemophilia and other inherited bleeding disorders.
Page D
Transfus Apher Sci; 2019 Oct; 58(5):565-568. PubMed ID: 31427262
[TBL] [Abstract][Full Text] [Related]
3. Congenital bleeding disorders. Rational treatment options.
Seremetis SV; Aledort LM
Drugs; 1993 Apr; 45(4):541-7. PubMed ID: 7684674
[TBL] [Abstract][Full Text] [Related]
4. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
Cochrane Database Syst Rev; 2015 Dec; (12):CD011385. PubMed ID: 26704192
[TBL] [Abstract][Full Text] [Related]
5. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease.
Josephson CD; Abshire TC
Best Pract Res Clin Haematol; 2006; 19(1):35-49. PubMed ID: 16377540
[TBL] [Abstract][Full Text] [Related]
6. Inherited bleeding disorders.
Blanchette VS; Sparling C; Turner C
Baillieres Clin Haematol; 1991 Apr; 4(2):291-332. PubMed ID: 1912663
[TBL] [Abstract][Full Text] [Related]
7. Drug therapy reviews: clinical use of hemostatic agents.
Lowe GD; Lawson DH
Am J Hosp Pharm; 1978 Apr; 35(4):414-22. PubMed ID: 306196
[TBL] [Abstract][Full Text] [Related]
8. Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.
Berntorp E; Astermark J; Baghaei F; Bergqvist D; Holmström M; Ljungberg B; Norlund A; Palmblad J; Petrini P; Stigendal L; Säwe J
Haemophilia; 2012 Mar; 18(2):158-65. PubMed ID: 22151198
[TBL] [Abstract][Full Text] [Related]
9. [The treatment of inherited coagulation disorders].
Blombäck M; Nilsson IM
Lakartidningen; 1972 Dec; 69():Suppl 4:76-84. PubMed ID: 4540328
[No Abstract] [Full Text] [Related]
10. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.
Coppola A; Franchini M; Makris M; Santagostino E; Di Minno G; Mannucci PM
Haemophilia; 2012 May; 18(3):e173-87. PubMed ID: 22335611
[TBL] [Abstract][Full Text] [Related]
11. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.
Franchini M; Makris M; Santagostino E; Coppola A; Mannucci PM
Haemophilia; 2012 May; 18(3):e164-72. PubMed ID: 22250981
[TBL] [Abstract][Full Text] [Related]
12. Surgical care of patients with hereditary disorders of blood coagulation.
Shulman NR
Mod Treat; 1968 Jan; 5(1):61-83. PubMed ID: 4870180
[No Abstract] [Full Text] [Related]
13. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.
United Kingdom Haemophelia Centre Doctors' Organisation
Haemophilia; 2003 Jan; 9(1):1-23. PubMed ID: 12558775
[TBL] [Abstract][Full Text] [Related]
14. Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Asatiani E; Kessler CM;
Haemophilia; 2007 Nov; 13(6):685-96. PubMed ID: 17973844
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
Iorio A; Matino D; D'Amico R; Makris M
Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
[TBL] [Abstract][Full Text] [Related]
16. Pioneering designs for recombinant coagulation factors.
Schulte S
Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
[TBL] [Abstract][Full Text] [Related]
17. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
18. The future of plasma-derived clotting factor concentrates.
Hoots WK
Haemophilia; 2001 Jan; 7 Suppl 1():4-9. PubMed ID: 11240612
[TBL] [Abstract][Full Text] [Related]
19. Inherited Bleeding Disorders in the Obstetric Patient.
Bannow BS; Konkle BA
Transfus Med Rev; 2018 Oct; 32(4):237-243. PubMed ID: 30097224
[TBL] [Abstract][Full Text] [Related]
20. Emergency department care for patients with hemophilia and von Willebrand disease.
Singleton T; Kruse-Jarres R; Leissinger C
J Emerg Med; 2010 Aug; 39(2):158-65. PubMed ID: 18757163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
